Previous close | 1.2200 |
Open | 1.2200 |
Bid | 0.2500 |
Ask | 1.7500 |
Strike | 340.00 |
Expiry date | 2025-01-17 |
Day's range | 1.2200 - 1.2200 |
Contract range | N/A |
Volume | |
Open interest | 346 |
Shares of Eli Lilly (LLY) are slightly above their flatline Wednesday morning after the pharmaceutical giant announced positive results from a clinical trial of GLP-1 its weight loss drug Zepbound. The trial revealed that the drug helped patients with sleep apnea, a condition characterized by irregular breathing during sleep. The company is now moving to apply for an expanded label from the US Food and Drug Administration (FDA). If approved, it would allow Zepbound to be prescribed and used for the treatment of sleep apnea, in addition to its current weight loss use. Yahoo Finance's Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode. This post was written by Angel Smith
In this article, we discuss 14 best large-cap dividend growth stocks to buy now. You can skip our detailed analysis of large-cap dividend stocks and their historical performance, and go directly to read 5 Best Large Cap Dividend Growth Stocks To Buy Now. Large-cap stocks have remained ideal for investors as they typically form the […]
Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo are included in this Analyst Blog.